PD51-02 PLANNED SECONDARY ANALYSIS OF PURE-01: ROLE OF FDG-PET/CT IN EVALUATING LYMPH NODE INVOLVEMENT OF PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER (MIBC) RECEIVING NEOADJUVANT PEMBROLIZUMAB AND RADICAL CYSTECTOMY (RC)